Rallybio Corporation Acquires Candid Therapeutics

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Treadwell Therapeutics Acquires TCRyption Inc.

October 15, 2021

Biotechnology

Treadwell Therapeutics announced it has acquired TCRyption Inc., a TIO Bioventures–backed developer of a novel TCR-identification platform for T cell therapies, in a stock-swap transaction. The acquisition brings the TCRypt platform and a bank of TCR candidates into Treadwell's pre-clinical oncology pipeline to expand its cell-therapy capabilities, with initial TCR programs expected to enter the clinic in early 2023.

Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

March 6, 2023

Healthcare Services

Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.

Sesen Bio and Carisma Therapeutics Announce Definitive Merger Agreement

September 21, 2022

Biotechnology

Sesen Bio, Inc. and Carisma Therapeutics Inc. have entered into a definitive merger agreement in an all-stock transaction to combine their businesses and create a well-funded, clinical-stage biotechnology company focused on engineered macrophage cell therapies for cancer and other serious disorders. The combined company is expected to trade on Nasdaq as Carisma Therapeutics Inc. under the ticker “CARM” and have approximately $180 million in cash at close, including $30 million from a concurrent financing by Carisma.

Cyclerion Therapeutics to Merge With Korsana Biosciences in All-Stock Deal

April 1, 2026

Healthcare Services

Cyclerion Therapeutics and Korsana Biosciences have entered into a definitive merger agreement in an all-stock transaction, with the combined company to operate under the Korsana Biosciences name and trade on Nasdaq as KRSA. The merger is supported by an oversubscribed private financing expected to generate approximately $380 million in gross proceeds to fund Korsana operations into 2029.

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.